🇺🇸 ACT-293987 in United States

12 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 12

Most-reported reactions

1. Caesarean Section — 2 reports (16.67%)
2. Pregnancy Of Partner — 2 reports (16.67%)
3. Abortion Missed — 1 report (8.33%)
4. Amniocentesis — 1 report (8.33%)
5. Exposure During Pregnancy — 1 report (8.33%)
6. Live Birth — 1 report (8.33%)
7. Maternal Exposure Before Pregnancy — 1 report (8.33%)
8. Pregnancy — 1 report (8.33%)
9. Premature Baby — 1 report (8.33%)
10. Uterine Dilation And Evacuation — 1 report (8.33%)

Source database →

Frequently asked questions

Is ACT-293987 approved in United States?

ACT-293987 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for ACT-293987 in United States?

Actelion is the originator. The local marketing authorisation holder may differ — check the official source linked above.